<div id="readability-page-1">Goldman Sachs analysts last week noted that hedge funds in Q3 2025 rotated away from consumer discretionary stocks into health care. That increase in the pharma space was concentrated in biotech. Below is Goldman's list of those health care stocks that saw the largest net increases in popularity among hedge funds in the quarter, ranked according to...</div>

OCUL

百時美施貴寶

福泰制藥

<p>高盛分析師報告稱，2025 年第三季度對沖基金的投資從消費品類股票轉向醫療保健股票，特別是生物技術領域。Vertex Pharmaceuticals、百時美施貴寶和 Ocular Therapeutix 是評級最高的股票，具有強勁的 Seeking Alpha 量化評級。該評級系統根據估值、增長、盈利能力和動量對股票進行評估，評級超過 3.5 被視為看漲</p>

SA Quant 對高盛的醫療保健股票進行排名，這些股票在對沖基金中的受歡迎程度增長幅度最大